Lysis in Medical Technology
Navigation Links
Lysis in Medical Technology
- Results Presented at ASH Annual Meeting-
SAN FRANCISCO, Dec. 6 /PRNewswire-FirstCall/ -- Sanofi-aventis today announced results of a randomized phase III study presented at the 50th Annual Meeting of the American Society of Hematology. The study in adult patients with hematological mali...
...antibody for the treatment of patients with KRAS- and BRAF-mutated colorectal cancer is now possible." (1)Lutterbuese, R. et al. Highly efficient lysis of KRAS- and BRAF-mutated human colon cancer cells by T cell-engaging BiTE antibodies derived from anti-EGFR antibodies cetuximab and panitumumab AAC...
...diac and pulmonary disorders, reversible posterior leukoencephalopathy syndrome, gastrointestinal adverse events, thrombocytopenia, neutropenia, tumor lysis syndrome and hepatic events. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Nursing mothers are advi...
...diac and pulmonary disorders, reversible posterior leukoencephalopathy syndrome, gastrointestinal adverse events, thrombocytopenia, neutropenia, tumor lysis syndrome and hepatic events. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Nursing mothers are advi...
...within eight weeks from start of treatment) occurred in four patients (7 percent) in the DR group and two patients (3 percent) in the BFR group. Tumor lysis syndrome was also reported following treatment with ofatumumab. Common adverse reactions (greater than or equal to 10%) were pyrexia, cough, diarrhea,...
...diac and pulmonary disorders, reversible posterior leukoencephalopathy syndrome, gastrointestinal adverse events, thrombocytopenia, neutropenia, tumor lysis syndrome and hepatic events. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Nursing mothers are advi...
...te a phase 2 study investigating the activity of adecatumumab in colon cancer patients with completely resected liver metastases." (1) ADCC-mediated lysis of KRAS-mutated Colon Cancer Cells by Anti-EpCAM Antibody Adecatumumab. D. Ruttinger et al. 23rd annual meeting of iSBTc, San Diego Nov. 1st (2008; ab...
... high levels in cancer cells. To enhance product efficacy, JX-594 is also engineered to express the GM-CSF protein. GM-CSF complements the cancer cell lysis work of the product candidate, leading to a cascade of events resulting in tumor necrosis, tumor vasculature shutdown and an anti-tumoral immune attac...
... high levels in cancer cells. To enhance product efficacy, JX-594 is also engineered to express the GM-CSF protein. GM-CSF complements the cancer cell lysis work of the product candidate, leading to a cascade of events resulting in tumor necrosis, tumor vasculature shutdown and an anti-tumoral immune attac...
...form Act of 1995. These statements include the finalization of paperwork with the NIH and work commencement; the reported effectiveness of PCT in cell lysis and isolation of subcellular molecular complexes, including organelles; the speed, reproducibility, quality, and simplicity of sample preparation usin...
...ration of Clolar results in a rapid reduction of peripheral leukemia cells. Patients should be evaluated and monitored for signs and symptoms of tumor lysis syndrome and cytokine release (e.g., tachypnea, tachycardia, hypotension, pulmonary edema) that could develop into systemic inflammatory response synd...
...hy, hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor periphera...
...hy, hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor periphera...
...hy, hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor periphera...
... IgE target antigens, all showed high potency as demonstrated by redirected lysis of respective target cells at half maximal concentrations below 1 ng/ml (18...antibodies how to recruit T cells for a very selective and highly effective lysis of target cells. Proof of concept has been established for the BiTE platfor...
...alone group had adverse events that resulted in death, including two patients in the Genasense group who died from complications associated with tumor lysis and infusion-related reactions. A scientific report of the safety and efficacy findings from this study was published earlier this year in the Journ...
...hy, hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor periphera...
...hy, hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor periphera...
...hy, hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor periphera...
...hy, hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor periphera...
...fibrillation and cardiogenic shock. Acute renal failure requiring dialysis with instances of fatal outcome has been reported in the setting of tumor lysis syndrome following treatment with Rituxan in patients with NHL. Severe mucocutaneous skin reactions, some with fatal outcome, have been reported in ...
...fibrillation and cardiogenic shock. Acute renal failure requiring dialysis with instances of fatal outcome has been reported in the setting of tumor lysis syndrome following treatment with Rituxan in patients with NHL. Severe mucocutaneous skin reactions, some with fatal outcome, have been reported in ...
...hy, hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor periphera...
...feeder cells to which the original hESC cell line was exposed in its initial derivation. Expression of such non-human antigens would typically lead to lysis by antibodies present in the sera of normal individuals. In the studies, GRNOPC1 cells were tested for susceptibility to both immune effector cells ...
...cohort 4 has completed two cycles of treatment, and stable disease has been observed. A second patient has had clinical findings consistent with tumor lysis syndrome, a transient metabolic abnormality resulting from the rapid destruction of malignant cells. This patient experienced a transient reduction in...
...hy, hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor periphera...
...hy, hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor periphera...
...hy, hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor periphera...
...hy, hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor periphera...
...antibody for the treatment of patients with KRAS- and BRAF-mutated colorectal cancer is now possible." (1)Lutterbuese, R. et al. Highly efficient lysis of KRAS- and BRAF-mutated human colon cancer cells by T cell-engaging BiTE antibodies derived from anti-EGFR antibodies cetuximab and panitumumab AAC...
Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer
... high levels in cancer cells. To enhance product efficacy, JX-594 is also engineered to express the GM-CSF protein. GM-CSF complements the cancer cell lysis work of the product candidate, leading to a cascade of events resulting in tumor necrosis, tumor vasculature shutdown and an anti-tumoral immune attac......diac and pulmonary disorders, reversible posterior leukoencephalopathy syndrome, gastrointestinal adverse events, thrombocytopenia, neutropenia, tumor lysis syndrome and hepatic events. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Nursing mothers are advi...
New Study Shows PCR and FCR Have Significant Activity in B-cell Chronic Lymphocytic Leukemia
...wn: Superiority of Rasuburicase vs. Allopurinol on serum uric acid control in adult patients with hematologic malignancies at risk of developing Tumor lysis Syndrome Multiple Myeloma Jeffrey Matous, M.D., Rocky Mountain Cancer Centers-Midtown: Phase II study of......diac and pulmonary disorders, reversible posterior leukoencephalopathy syndrome, gastrointestinal adverse events, thrombocytopenia, neutropenia, tumor lysis syndrome and hepatic events. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Nursing mothers are advi...
...within eight weeks from start of treatment) occurred in four patients (7 percent) in the DR group and two patients (3 percent) in the BFR group. Tumor lysis syndrome was also reported following treatment with ofatumumab. Common adverse reactions (greater than or equal to 10%) were pyrexia, cough, diarrhea,...
...diac and pulmonary disorders, reversible posterior leukoencephalopathy syndrome, gastrointestinal adverse events, thrombocytopenia, neutropenia, tumor lysis syndrome and hepatic events. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Nursing mothers are advi...
...te a phase 2 study investigating the activity of adecatumumab in colon cancer patients with completely resected liver metastases." (1) ADCC-mediated lysis of KRAS-mutated Colon Cancer Cells by Anti-EpCAM Antibody Adecatumumab. D. Ruttinger et al. 23rd annual meeting of iSBTc, San Diego Nov. 1st (2008; ab...
... high levels in cancer cells. To enhance product efficacy, JX-594 is also engineered to express the GM-CSF protein. GM-CSF complements the cancer cell lysis work of the product candidate, leading to a cascade of events resulting in tumor necrosis, tumor vasculature shutdown and an anti-tumoral immune attac...
InVitria Showcases Cell Culture Productivity Enhancers at BioProcess International
...romotant as a cell culture ingredient in mammalian cell culture media. (see http://www.Lacromin.com ) -- Lysobac -- Lysobac is a bacterial cell lysis agent that is more efficient and more consistent compared to chicken lysozyme and provides higher protein yield compared with mechanical cell ...... high levels in cancer cells. To enhance product efficacy, JX-594 is also engineered to express the GM-CSF protein. GM-CSF complements the cancer cell lysis work of the product candidate, leading to a cascade of events resulting in tumor necrosis, tumor vasculature shutdown and an anti-tumoral immune attac...
...form Act of 1995. These statements include the finalization of paperwork with the NIH and work commencement; the reported effectiveness of PCT in cell lysis and isolation of subcellular molecular complexes, including organelles; the speed, reproducibility, quality, and simplicity of sample preparation usin...
...ration of Clolar results in a rapid reduction of peripheral leukemia cells. Patients should be evaluated and monitored for signs and symptoms of tumor lysis syndrome and cytokine release (e.g., tachypnea, tachycardia, hypotension, pulmonary edema) that could develop into systemic inflammatory response synd...
...hy, hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor periphera...
...hy, hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor periphera...
Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
... high levels in cancer cells. To enhance product efficacy, JX-594 is also engineered to express the GM-CSF protein. GM-CSF complements the cancer cell lysis work of the product candidate, leading to a cascade of events resulting in tumor necrosis, tumor vasculature shutdown and an anti-tumoral immune attac......hy, hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor periphera...
... IgE target antigens, all showed high potency as demonstrated by redirected lysis of respective target cells at half maximal concentrations below 1 ng/ml (18...antibodies how to recruit T cells for a very selective and highly effective lysis of target cells. Proof of concept has been established for the BiTE platfor...
Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkin's Lymphoma
...hy, hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor periphera......alone group had adverse events that resulted in death, including two patients in the Genasense group who died from complications associated with tumor lysis and infusion-related reactions. A scientific report of the safety and efficacy findings from this study was published earlier this year in the Journ...
Twelve DOXIL(R) Clinical Studies to be Presented at American Society of Hematology Annual Meeting
...hy, hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor periphera...Genzyme Completes Enrollment in Pivotal, Phase 2 Clinical Trial of Clofarabine in Adult AML
...ration of Clolar results in a rapid reduction of peripheral leukemia cells. Patients should be evaluated and monitored for signs and symptoms of tumor lysis syndrome and cytokine release (e.g., tachypnea, tachycardia, hypotension, pulmonary edema) that could develop into systemic inflammatory response synd......hy, hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor periphera...
...hy, hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor periphera...
...hy, hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor periphera...
...hy, hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor periphera...
...fibrillation and cardiogenic shock. Acute renal failure requiring dialysis with instances of fatal outcome has been reported in the setting of tumor lysis syndrome following treatment with Rituxan in patients with NHL. Severe mucocutaneous skin reactions, some with fatal outcome, have been reported in ...
...fibrillation and cardiogenic shock. Acute renal failure requiring dialysis with instances of fatal outcome has been reported in the setting of tumor lysis syndrome following treatment with Rituxan in patients with NHL. Severe mucocutaneous skin reactions, some with fatal outcome, have been reported in ...
...hy, hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor periphera...
Santaris Pharma Presents Positive Clinical Data on SPC2996 in Chronic Lymphocytic Leukaemia
...patients recovered fully. Two cases of grade 3 thrombocytopaenia were reported. In the 2mg/kg/infusion group, one patient was diagnosed to have Tumour lysis Syndrome following 2 infusions of drug. - ENDS - Annabel Entress Account Manager -----------------------------------------------------------------......feeder cells to which the original hESC cell line was exposed in its initial derivation. Expression of such non-human antigens would typically lead to lysis by antibodies present in the sera of normal individuals. In the studies, GRNOPC1 cells were tested for susceptibility to both immune effector cells ...
...cohort 4 has completed two cycles of treatment, and stable disease has been observed. A second patient has had clinical findings consistent with tumor lysis syndrome, a transient metabolic abnormality resulting from the rapid destruction of malignant cells. This patient experienced a transient reduction in...
...hy, hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor periphera...
...hy, hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor periphera...
...hy, hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor periphera...
...hy, hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor periphera...
Other TagsProbeProbeProbeProbeProbeInterestSchoolSchoolRulingCourtCourtCourtProcessProcessProcessProcessProcessEffortsEffortsOther Contentshemorrhoidshemostasishemostasisencephalopathyencephalopathyencephalopathyhepatichepatichepatichepatichepatichepatomegalyhepatomegalyherniashernias
(Date:11/26/2009)...MRSA (methicillin-resistant Staphylococcus Aureus...nihilation as low-temperature plasma prototype dev...y and unfailing bactericidal cocktails. , Two pr...ient disinfection of healthy skin (e.g. hands and ...a can pose a lethal threat; and another to shoot b...
(Date:11/25/2009)... Dr. Sarit Larisch, Head of the Cell Death Resear...ent of Biology, has been awarded the prestigious J...earch exploring the cause of brain cell damage in ...ach year to scientists in support of innovation an...d officially conferred earlier this month at an ev...
(Date:11/24/2009)...For thousands of years it has been prescribed by t...ilments from headaches and stomach pain to fever a...Newcastle University have been able to scientifica... crenata otherwise known as Brazilian mint. , T...he team led by researcher Graciela Rocha was able ...
Breaking Biology News(10 mins):Plasma produces KO cocktail for MRSA 2Plasma produces KO cocktail for MRSA 3Johnson & Johnson award goes to research of the cause of brain cell damage in Parkinson's 2Got a pain? -- Have a cup of Brazilian mint 2Cadence Pharmaceuticals to Webcast October 7th Analyst Day 5086 1Cadence Pharmaceuticals to Webcast October 7th Analyst Day 5086 2Cadence Pharmaceuticals to Webcast October 7th Analyst Day 5086 3Cord Blood America Opens Las Vegas Cryogenic Laboratory 3B Consolidates Offices in Nevada 58510 1Cord Blood America Opens Las Vegas Cryogenic Laboratory 3B Consolidates Offices in Nevada 58510 2Cord Blood America Opens Las Vegas Cryogenic Laboratory 3B Consolidates Offices in Nevada 58510 3US Farms Inc Announces Distribution Partnership With Natures Best 58507 1US Farms Inc Announces Distribution Partnership With Natures Best 58507 2US Farms Inc Announces Distribution Partnership With Natures Best 58507 3(Date:11/29/2009)... Moravia,s Nanjing-based Service Deliver...ce , Brno, Czech Republic...tion solution provider, is pleased to announce its... 2009, to be held in Nanjing, China, on November 3...Union-based companies that have established and gr...
(Date:11/29/2009)... CA--New connections begin to form between brain c...k, according to a study published this week in Na...ifornia, Santa Cruz, the study involved detailed o...ace in the brain during motor learning. , The re...ch through a slot to get a seed. They observed rap...
(Date:11/29/2009)...aware the sleep disorder boosts urine production, ...Day News) -- People who wake up during the night t...al problem. Sleep apnea, a breathing-related sleep...ggests that nighttime urination, or nocturia, is c...ive sleep apnea, a disorder in which soft tissue i...
(Date:11/28/2009)...HICAGO, Nov. 28 Get ready for a... the clinical routine when Siemens introduces ...ly and Annual Meeting of the Radiological Society ...er 3 at McCormick Place (Booth #825, East Building...o. via , Siemens, new imaging software for mu...
(Date:11/27/2009)...DFORD, Mass., Nov. 27 GS...a supplier of precision technology products and se...l meeting of the Company,s shareholders has been s... location of the meeting will be announced in due ...ived a requisition notice from Stephen Bershad, a ...
Breaking Medicine News(10 mins):Health News:Moravia Worldwide to Participate in the 5th EU-China Business Summit 2009 in Nanjing China 2Health News:Study shows new brain connections form rapidly during motor learning 2Health News:Study shows new brain connections form rapidly during motor learning 3Health News:Sleep Apnea May Cause Nighttime Urination 2Health News:Sleep Apnea May Cause Nighttime Urination 3Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 2Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 3Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 4Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 5Health News:GSI Group Calls Shareholders Meeting 2[0] Moravia Worldwide to Participate in the 5th EU-China Business Summit 2009 in Nanjing China [0] Study shows new brain connections form rapidly during motor learning[1] Sleep Apnea May Cause Nighttime Urination[1] Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via[0] GSI Group Calls Shareholders Meeting
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |